tetano
Editor, Senior Moderator
J Rheumatol
. 2022 Jan 15;jrheum.210863.
doi: 10.3899/jrheum.210863. Online ahead of print.
Safety profile and low risk of disease relapse after BNT162b2 mRNA SARS-COV-2 vaccination in patients with rare rheumatic diseases
Marco Fornaro[SUP] 1 [/SUP], Vincenzo Venerito[SUP] 1 [/SUP], Florenzo Iannone[SUP] 1 [/SUP], Fabio Cacciapaglia[SUP] 1 [/SUP]
Affiliations
Abstract
Vaccination today represents the first defence against the effects of the Coronavirus disease 2019, mainly in rheumatic patients, where an increased risk for hospitalization and death has been reported (1,2). The previous studies on the safety and tolerability of BNT162b2 mRNA-SARS-CoV-2 (3) vaccine in patients affected with rheumatic diseases(RDs) included predominantly patients with inflammatory arthritis (4-6). This study was focused on patients affected with rare RDs and systemic lupus erythematosus (SLE) to assess the safety of the BNT162b2 mRNA SARS-CoV-2 vaccine and possible disease flares after vaccination.
. 2022 Jan 15;jrheum.210863.
doi: 10.3899/jrheum.210863. Online ahead of print.
Safety profile and low risk of disease relapse after BNT162b2 mRNA SARS-COV-2 vaccination in patients with rare rheumatic diseases
Marco Fornaro[SUP] 1 [/SUP], Vincenzo Venerito[SUP] 1 [/SUP], Florenzo Iannone[SUP] 1 [/SUP], Fabio Cacciapaglia[SUP] 1 [/SUP]
Affiliations
- PMID: 35033998
- DOI: 10.3899/jrheum.210863
Abstract
Vaccination today represents the first defence against the effects of the Coronavirus disease 2019, mainly in rheumatic patients, where an increased risk for hospitalization and death has been reported (1,2). The previous studies on the safety and tolerability of BNT162b2 mRNA-SARS-CoV-2 (3) vaccine in patients affected with rheumatic diseases(RDs) included predominantly patients with inflammatory arthritis (4-6). This study was focused on patients affected with rare RDs and systemic lupus erythematosus (SLE) to assess the safety of the BNT162b2 mRNA SARS-CoV-2 vaccine and possible disease flares after vaccination.